Imprimis Pharmaceuticals has entered a strategic development and investment agreement with Professional Compounding Centers of America (PCCA), under which the companies will develop and share drug-formulation technology aimed at developing treatments for muscle and joint pain, neuropathic pain and other conditions. As part of the deal, PCCA has made a $4 million equity investment in Imprimis.   The agreement gives Imprimis access to PCCA’s topical technologies and formulation expertise for...